(INNS)
XELIGEKIMAB(INND)
XELIGEKIMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS IL17A (INTERLEUKIN 17A, IL-17A)], MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN (1-454) [VH (HOMO SAPIENS IGHV3-7*01 (88.8%) -(IGHD) -IGHJ2*01 (100%), CDR-IMGT [8.8.20] (26-33.51-58.97-116)) (1-127)- HOMO SAPIENS IGHG4*01, G4V5 H P10 (CH1 (128- 225), HINGE 1-12 S10>P (235) (226-237), CH2 (238- 347), CH3 (348-452), CHS (453-454)) (128-454)], (141-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [VKAPPA (HOMO SAPIENS IGKV1-6*01 (89.1%) - IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89- 97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')]; DIMER (233- 233'':236-236'')-BISDISULFIDE, PRODUCED IN A CHINESE HAMSTER OVARY (CHO)-S CELL LINE, GLYCOFORM ALFA(WHO)
XELIGEKIMABUM(INN)